Literature DB >> 22593021

Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation.

Thorsten R Doeppner1, Tobias A S Ewert, Lars Tönges, Josephine Herz, Anil Zechariah, Ayman ElAli, Anna-Kristin Ludwig, Bernd Giebel, Florian Nagel, Gunnar P H Dietz, Jens Weise, Dirk M Hermann, Mathias Bähr.   

Abstract

Novel therapeutic concepts against cerebral ischemia focus on cell-based therapies in order to overcome some of the side effects of thrombolytic therapy. However, cell-based therapies are hampered because of restricted understanding regarding optimal cell transplantation routes and due to low survival rates of grafted cells. We therefore transplanted adult green fluorescence protein positive neural precursor cells (NPCs) either intravenously (systemic) or intrastriatally (intracerebrally) 6 hours after stroke in mice. To enhance survival of NPCs, cells were in vitro protein-transduced with TAT-heat shock protein 70 (Hsp70) before transplantation followed by a systematic analysis of brain injury and underlying mechanisms depending on cell delivery routes. Transduction of NPCs with TAT-Hsp70 resulted in increased intracerebral numbers of grafted NPCs after intracerebral but not after systemic transplantation. Whereas systemic delivery of either native or transduced NPCs yielded sustained neuroprotection and induced neurological recovery, only TAT-Hsp70-transduced NPCs prevented secondary neuronal degeneration after intracerebral delivery that was associated with enhanced functional outcome. Furthermore, intracerebral transplantation of TAT-Hsp70-transduced NPCs enhanced postischemic neurogenesis and induced sustained high levels of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and vascular endothelial growth factor in vivo. Neuroprotection after intracerebral cell delivery correlated with the amount of surviving NPCs. On the contrary, systemic delivery of NPCs mediated acute neuroprotection via stabilization of the blood-brain-barrier, concomitant with reduced activation of matrix metalloprotease 9 and decreased formation of reactive oxygen species. Our findings imply two different mechanisms of action of intracerebrally and systemically transplanted NPCs, indicating that systemic NPC delivery might be more feasible for translational stroke concepts, lacking a need of in vitro manipulation of NPCs to induce long-term neuroprotection.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593021     DOI: 10.1002/stem.1098

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  43 in total

1.  The Neural Cell Adhesion Molecule-Derived (NCAM)-Peptide FG Loop (FGL) Mobilizes Endogenous Neural Stem Cells and Promotes Endogenous Regenerative Capacity after Stroke.

Authors:  Rebecca Klein; Nicolas Mahlberg; Maurice Ohren; Anne Ladwig; Bernd Neumaier; Rudolf Graf; Mathias Hoehn; Morten Albrechtsen; Stephen Rees; Gereon Rudolf Fink; Maria Adele Rueger; Michael Schroeter
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

Review 2.  Opportunities and challenges: stem cell-based therapy for the treatment of ischemic stroke.

Authors:  Yao-Hui Tang; Yuan-Yuan Ma; Zhi-Jun Zhang; Yong-Ting Wang; Guo-Yuan Yang
Journal:  CNS Neurosci Ther       Date:  2015-02-10       Impact factor: 5.243

3.  TAT-Hsp70 induces neuroprotection against stroke via anti-inflammatory actions providing appropriate cellular microenvironment for transplantation of neural precursor cells.

Authors:  Thorsten R Doeppner; Britta Kaltwasser; Jin Fengyan; Dirk M Hermann; Mathias Bähr
Journal:  J Cereb Blood Flow Metab       Date:  2013-07-24       Impact factor: 6.200

Review 4.  Mannitol-enhanced delivery of stem cells and their growth factors across the blood-brain barrier.

Authors:  Gabriel S Gonzales-Portillo; Paul R Sanberg; Max Franzblau; Chiara Gonzales-Portillo; Theo Diamandis; Meaghan Staples; Cyndy D Sanberg; Cesar V Borlongan
Journal:  Cell Transplant       Date:  2014-01-29       Impact factor: 4.064

5.  Conditioned Medium Derived from Neural Progenitor Cells Induces Long-term Post-ischemic Neuroprotection, Sustained Neurological Recovery, Neurogenesis, and Angiogenesis.

Authors:  Thorsten R Doeppner; Viktorija Traut; Alexander Heidenreich; Britta Kaltwasser; Bert Bosche; Mathias Bähr; Dirk M Hermann
Journal:  Mol Neurobiol       Date:  2016-02-09       Impact factor: 5.590

Review 6.  Heat shock proteins in the brain: role of Hsp70, Hsp 27, and HO-1 (Hsp32) and their therapeutic potential.

Authors:  Frank R Sharp; Xinhua Zhan; Da-Zhi Liu
Journal:  Transl Stroke Res       Date:  2013-08-03       Impact factor: 6.829

7.  Ischemic Post-Conditioning Induces Post-Stroke Neuroprotection via Hsp70-Mediated Proteasome Inhibition and Facilitates Neural Progenitor Cell Transplantation.

Authors:  Thorsten R Doeppner; Maria Doehring; Britta Kaltwasser; Arshad Majid; Fengyan Lin; Mathias Bähr; Ertugrul Kilic; Dirk M Hermann
Journal:  Mol Neurobiol       Date:  2016-10-03       Impact factor: 5.590

8.  Lithium-induced neuroprotection in stroke involves increased miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination by GSK3β inhibition-independent pathways.

Authors:  Thorsten R Doeppner; Britta Kaltwasser; Eduardo H Sanchez-Mendoza; Ahmet B Caglayan; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

9.  Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression.

Authors:  Thorsten R Doeppner; Josephine Herz; André Görgens; Jana Schlechter; Anna-Kristin Ludwig; Stefan Radtke; Kyra de Miroschedji; Peter A Horn; Bernd Giebel; Dirk M Hermann
Journal:  Stem Cells Transl Med       Date:  2015-09-03       Impact factor: 6.940

Review 10.  Cell-based therapy for ischemic stroke.

Authors:  Jing Zhang; Michael Chopp
Journal:  Expert Opin Biol Ther       Date:  2013-06-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.